Let's round out our big block of pharmaceutical updates by adding a new pick to our portfolio.
If you've been following us all week, there have been some huge updates to the pharmaceutical landscape that are about to pay big dividends for investors.
Our analysts believe the biggest new battleground for the decade will be cancer and cancer treatments.
As America's largest generation ever ages into the highest risk bracket to hit a cancer diagnosis, big pharma is hitting back with wild new technologies that are making cancer way more treatable, and those treatments are far "gentler" than they ever have been.
One of the strongest new entries to the cancer battleground is the British-Swedish old guard: AstraZeneca ($AZN).
After posting a few solid years of growth, AZN is finally coming out of the shadow of Pfizer -- aka the pharma giant that tried to take them over a decade ago. AZN is the fastest-growing pharma-play across the pond and is now the largest company on the London Stock Exchange.
A lot of that growth has come from solid management and a broad pipeline. But a lot more of it is about to come from AstraZeneca's new front in the war on cancer.
AZN has a pretty wild spin on novel cancer treatments. Instead of brutal, broad chemotherapies, AZN has developed a class of drugs that act as cancer-seeking missiles, which attack some of the worst kinds of tumors without the damage traditional chemo can cause.
Developing the "brains" of these missiles used to be really taxing for R&D, but AZN has figured out a wild new strategy that uses AI to develop these cancer-seeking missiles.
This new class of drugs is one of many wild new updates coming out of AZN. Their late-stage pipeline is robust and we're about to kick off a few years of fast-paced growth.
And all of this growth is coming despite a complete collapse of revenue from COVID-19 therapies.
It's a great time to start chipping away at some of the world's biggest health issues, so let's dive through the details and see how AstraZeneca is pulling it off 👇